Diffuse large B-cell lymphoma: new targets and novel therapies

Bruce D. Cheson, Grzegorz Nowakowski, Gilles Salles

Research output: Contribution to journalReview articlepeer-review


Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and rituximab, selinexor, and tafasitamab plus lenalidomide. Three CAR-T cell products are currently approved by the FDA, with others in clinical trials. Additional agents in development include bispecific antibodies and antibody drug conjugates. Combinations of targeted therapies should lead to further improvement in the outcome of patients with B-cell malignancies.

Original languageEnglish (US)
Article number68
JournalBlood cancer journal
Issue number4
StatePublished - Apr 2021

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Diffuse large B-cell lymphoma: new targets and novel therapies'. Together they form a unique fingerprint.

Cite this